ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global CD47 (IAP) Market Research Report 2025
Published Date: February 2025
|
Report Code: QYRE-Auto-8Q10809
Home | Market Reports | Health| Pharmacy
Global CD47 IAP Market Research Report 2022
BUY CHAPTERS

Global CD47 (IAP) Market Research Report 2025

Code: QYRE-Auto-8Q10809
Report
February 2025
Pages:96
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Gilead
Innovent Biologics
Akeso, Inc.
Sorrento Therapeutics
ZAI LAB
Hengrui
Surface Oncology
TG Therapeutics
Arch Oncology
ImmuneOncia Therapeutics
I-MAB
ImmuneOnco
Beijing Mab-works
Hanxbio
ALX Oncology
EpicentRx

CD47 (IAP) Market

The global market for CD47 (IAP) was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for CD47 (IAP) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for CD47 (IAP) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for CD47 (IAP) in Solid Tumor is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of CD47 (IAP) include Gilead, Innovent Biologics, Akeso, Inc, Arch Oncology, ImmuneOncia Therapeutics, I-MAB, Sorrento Therapeutics, Zai Lab, ImmuneOnco, Hengrui, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for CD47 (IAP), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CD47 (IAP).
The CD47 (IAP) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global CD47 (IAP) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CD47 (IAP) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of CD47 (IAP) Market Report

Report Metric Details
Report Name CD47 (IAP) Market
Segment by Type
Segment by Application
  • Solid Tumor
  • Lymphoma
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Gilead, Innovent Biologics, Akeso, Inc, Arch Oncology, ImmuneOncia Therapeutics, I-MAB, Sorrento Therapeutics, Zai Lab, ImmuneOnco, Hengrui, Beijing Mab-works, Hanxbio, ALX Oncology, Surface Oncology, TG Therapeutics, EpicentRx
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of CD47 (IAP) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the CD47 (IAP) Market report?

Ans: The main players in the CD47 (IAP) Market are Gilead, Innovent Biologics, Akeso, Inc, Arch Oncology, ImmuneOncia Therapeutics, I-MAB, Sorrento Therapeutics, Zai Lab, ImmuneOnco, Hengrui, Beijing Mab-works, Hanxbio, ALX Oncology, Surface Oncology, TG Therapeutics, EpicentRx

What are the Application segmentation covered in the CD47 (IAP) Market report?

Ans: The Applications covered in the CD47 (IAP) Market report are Solid Tumor, Lymphoma, Others

What are the Type segmentation covered in the CD47 (IAP) Market report?

Ans: The Types covered in the CD47 (IAP) Market report are CD47 Monoclonal Antibody, CD47 Double Antibody, CD47 Fusion Protein

Recommended Reports

Cancer Therapy Markets

Immunotherapy & Antibodies

Lymphoma & Solid Tumor

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CD47 (IAP) Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 CD47 Monoclonal Antibody
1.2.3 CD47 Double Antibody
1.2.4 CD47 Fusion Protein
1.3 Market by Application
1.3.1 Global CD47 (IAP) Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Solid Tumor
1.3.3 Lymphoma
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global CD47 (IAP) Market Perspective (2020-2031)
2.2 Global CD47 (IAP) Growth Trends by Region
2.2.1 Global CD47 (IAP) Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 CD47 (IAP) Historic Market Size by Region (2020-2025)
2.2.3 CD47 (IAP) Forecasted Market Size by Region (2026-2031)
2.3 CD47 (IAP) Market Dynamics
2.3.1 CD47 (IAP) Industry Trends
2.3.2 CD47 (IAP) Market Drivers
2.3.3 CD47 (IAP) Market Challenges
2.3.4 CD47 (IAP) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CD47 (IAP) Players by Revenue
3.1.1 Global Top CD47 (IAP) Players by Revenue (2020-2025)
3.1.2 Global CD47 (IAP) Revenue Market Share by Players (2020-2025)
3.2 Global CD47 (IAP) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by CD47 (IAP) Revenue
3.4 Global CD47 (IAP) Market Concentration Ratio
3.4.1 Global CD47 (IAP) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CD47 (IAP) Revenue in 2024
3.5 Global Key Players of CD47 (IAP) Head office and Area Served
3.6 Global Key Players of CD47 (IAP), Product and Application
3.7 Global Key Players of CD47 (IAP), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 CD47 (IAP) Breakdown Data by Type
4.1 Global CD47 (IAP) Historic Market Size by Type (2020-2025)
4.2 Global CD47 (IAP) Forecasted Market Size by Type (2026-2031)
5 CD47 (IAP) Breakdown Data by Application
5.1 Global CD47 (IAP) Historic Market Size by Application (2020-2025)
5.2 Global CD47 (IAP) Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America CD47 (IAP) Market Size (2020-2031)
6.2 North America CD47 (IAP) Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America CD47 (IAP) Market Size by Country (2020-2025)
6.4 North America CD47 (IAP) Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CD47 (IAP) Market Size (2020-2031)
7.2 Europe CD47 (IAP) Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe CD47 (IAP) Market Size by Country (2020-2025)
7.4 Europe CD47 (IAP) Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CD47 (IAP) Market Size (2020-2031)
8.2 Asia-Pacific CD47 (IAP) Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific CD47 (IAP) Market Size by Region (2020-2025)
8.4 Asia-Pacific CD47 (IAP) Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CD47 (IAP) Market Size (2020-2031)
9.2 Latin America CD47 (IAP) Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America CD47 (IAP) Market Size by Country (2020-2025)
9.4 Latin America CD47 (IAP) Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CD47 (IAP) Market Size (2020-2031)
10.2 Middle East & Africa CD47 (IAP) Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa CD47 (IAP) Market Size by Country (2020-2025)
10.4 Middle East & Africa CD47 (IAP) Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Gilead
11.1.1 Gilead Company Details
11.1.2 Gilead Business Overview
11.1.3 Gilead CD47 (IAP) Introduction
11.1.4 Gilead Revenue in CD47 (IAP) Business (2020-2025)
11.1.5 Gilead Recent Development
11.2 Innovent Biologics
11.2.1 Innovent Biologics Company Details
11.2.2 Innovent Biologics Business Overview
11.2.3 Innovent Biologics CD47 (IAP) Introduction
11.2.4 Innovent Biologics Revenue in CD47 (IAP) Business (2020-2025)
11.2.5 Innovent Biologics Recent Development
11.3 Akeso, Inc
11.3.1 Akeso, Inc Company Details
11.3.2 Akeso, Inc Business Overview
11.3.3 Akeso, Inc CD47 (IAP) Introduction
11.3.4 Akeso, Inc Revenue in CD47 (IAP) Business (2020-2025)
11.3.5 Akeso, Inc Recent Development
11.4 Arch Oncology
11.4.1 Arch Oncology Company Details
11.4.2 Arch Oncology Business Overview
11.4.3 Arch Oncology CD47 (IAP) Introduction
11.4.4 Arch Oncology Revenue in CD47 (IAP) Business (2020-2025)
11.4.5 Arch Oncology Recent Development
11.5 ImmuneOncia Therapeutics
11.5.1 ImmuneOncia Therapeutics Company Details
11.5.2 ImmuneOncia Therapeutics Business Overview
11.5.3 ImmuneOncia Therapeutics CD47 (IAP) Introduction
11.5.4 ImmuneOncia Therapeutics Revenue in CD47 (IAP) Business (2020-2025)
11.5.5 ImmuneOncia Therapeutics Recent Development
11.6 I-MAB
11.6.1 I-MAB Company Details
11.6.2 I-MAB Business Overview
11.6.3 I-MAB CD47 (IAP) Introduction
11.6.4 I-MAB Revenue in CD47 (IAP) Business (2020-2025)
11.6.5 I-MAB Recent Development
11.7 Sorrento Therapeutics
11.7.1 Sorrento Therapeutics Company Details
11.7.2 Sorrento Therapeutics Business Overview
11.7.3 Sorrento Therapeutics CD47 (IAP) Introduction
11.7.4 Sorrento Therapeutics Revenue in CD47 (IAP) Business (2020-2025)
11.7.5 Sorrento Therapeutics Recent Development
11.8 Zai Lab
11.8.1 Zai Lab Company Details
11.8.2 Zai Lab Business Overview
11.8.3 Zai Lab CD47 (IAP) Introduction
11.8.4 Zai Lab Revenue in CD47 (IAP) Business (2020-2025)
11.8.5 Zai Lab Recent Development
11.9 ImmuneOnco
11.9.1 ImmuneOnco Company Details
11.9.2 ImmuneOnco Business Overview
11.9.3 ImmuneOnco CD47 (IAP) Introduction
11.9.4 ImmuneOnco Revenue in CD47 (IAP) Business (2020-2025)
11.9.5 ImmuneOnco Recent Development
11.10 Hengrui
11.10.1 Hengrui Company Details
11.10.2 Hengrui Business Overview
11.10.3 Hengrui CD47 (IAP) Introduction
11.10.4 Hengrui Revenue in CD47 (IAP) Business (2020-2025)
11.10.5 Hengrui Recent Development
11.11 Beijing Mab-works
11.11.1 Beijing Mab-works Company Details
11.11.2 Beijing Mab-works Business Overview
11.11.3 Beijing Mab-works CD47 (IAP) Introduction
11.11.4 Beijing Mab-works Revenue in CD47 (IAP) Business (2020-2025)
11.11.5 Beijing Mab-works Recent Development
11.12 Hanxbio
11.12.1 Hanxbio Company Details
11.12.2 Hanxbio Business Overview
11.12.3 Hanxbio CD47 (IAP) Introduction
11.12.4 Hanxbio Revenue in CD47 (IAP) Business (2020-2025)
11.12.5 Hanxbio Recent Development
11.13 ALX Oncology
11.13.1 ALX Oncology Company Details
11.13.2 ALX Oncology Business Overview
11.13.3 ALX Oncology CD47 (IAP) Introduction
11.13.4 ALX Oncology Revenue in CD47 (IAP) Business (2020-2025)
11.13.5 ALX Oncology Recent Development
11.14 Surface Oncology
11.14.1 Surface Oncology Company Details
11.14.2 Surface Oncology Business Overview
11.14.3 Surface Oncology CD47 (IAP) Introduction
11.14.4 Surface Oncology Revenue in CD47 (IAP) Business (2020-2025)
11.14.5 Surface Oncology Recent Development
11.15 TG Therapeutics
11.15.1 TG Therapeutics Company Details
11.15.2 TG Therapeutics Business Overview
11.15.3 TG Therapeutics CD47 (IAP) Introduction
11.15.4 TG Therapeutics Revenue in CD47 (IAP) Business (2020-2025)
11.15.5 TG Therapeutics Recent Development
11.16 EpicentRx
11.16.1 EpicentRx Company Details
11.16.2 EpicentRx Business Overview
11.16.3 EpicentRx CD47 (IAP) Introduction
11.16.4 EpicentRx Revenue in CD47 (IAP) Business (2020-2025)
11.16.5 EpicentRx Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Gilead
Innovent Biologics
Akeso, Inc.
Sorrento Therapeutics
ZAI LAB
Hengrui
Surface Oncology
TG Therapeutics
Arch Oncology
ImmuneOncia Therapeutics
I-MAB
ImmuneOnco
Beijing Mab-works
Hanxbio
ALX Oncology
EpicentRx
List of Tables
 Table 1. Global CD47 (IAP) Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of CD47 Monoclonal Antibody
 Table 3. Key Players of CD47 Double Antibody
 Table 4. Key Players of CD47 Fusion Protein
 Table 5. Global CD47 (IAP) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global CD47 (IAP) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global CD47 (IAP) Market Size by Region (2020-2025) & (US$ Million)
 Table 8. Global CD47 (IAP) Market Share by Region (2020-2025)
 Table 9. Global CD47 (IAP) Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 10. Global CD47 (IAP) Market Share by Region (2026-2031)
 Table 11. CD47 (IAP) Market Trends
 Table 12. CD47 (IAP) Market Drivers
 Table 13. CD47 (IAP) Market Challenges
 Table 14. CD47 (IAP) Market Restraints
 Table 15. Global CD47 (IAP) Revenue by Players (2020-2025) & (US$ Million)
 Table 16. Global CD47 (IAP) Market Share by Players (2020-2025)
 Table 17. Global Top CD47 (IAP) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD47 (IAP) as of 2024)
 Table 18. Ranking of Global Top CD47 (IAP) Companies by Revenue (US$ Million) in 2024
 Table 19. Global 5 Largest Players Market Share by CD47 (IAP) Revenue (CR5 and HHI) & (2020-2025)
 Table 20. Global Key Players of CD47 (IAP), Headquarters and Area Served
 Table 21. Global Key Players of CD47 (IAP), Product and Application
 Table 22. Global Key Players of CD47 (IAP), Date of Enter into This Industry
 Table 23. Mergers & Acquisitions, Expansion Plans
 Table 24. Global CD47 (IAP) Market Size by Type (2020-2025) & (US$ Million)
 Table 25. Global CD47 (IAP) Revenue Market Share by Type (2020-2025)
 Table 26. Global CD47 (IAP) Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 27. Global CD47 (IAP) Revenue Market Share by Type (2026-2031)
 Table 28. Global CD47 (IAP) Market Size by Application (2020-2025) & (US$ Million)
 Table 29. Global CD47 (IAP) Revenue Market Share by Application (2020-2025)
 Table 30. Global CD47 (IAP) Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 31. Global CD47 (IAP) Revenue Market Share by Application (2026-2031)
 Table 32. North America CD47 (IAP) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 33. North America CD47 (IAP) Market Size by Country (2020-2025) & (US$ Million)
 Table 34. North America CD47 (IAP) Market Size by Country (2026-2031) & (US$ Million)
 Table 35. Europe CD47 (IAP) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. Europe CD47 (IAP) Market Size by Country (2020-2025) & (US$ Million)
 Table 37. Europe CD47 (IAP) Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Asia-Pacific CD47 (IAP) Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Asia-Pacific CD47 (IAP) Market Size by Region (2020-2025) & (US$ Million)
 Table 40. Asia-Pacific CD47 (IAP) Market Size by Region (2026-2031) & (US$ Million)
 Table 41. Latin America CD47 (IAP) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Latin America CD47 (IAP) Market Size by Country (2020-2025) & (US$ Million)
 Table 43. Latin America CD47 (IAP) Market Size by Country (2026-2031) & (US$ Million)
 Table 44. Middle East & Africa CD47 (IAP) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Middle East & Africa CD47 (IAP) Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Middle East & Africa CD47 (IAP) Market Size by Country (2026-2031) & (US$ Million)
 Table 47. Gilead Company Details
 Table 48. Gilead Business Overview
 Table 49. Gilead CD47 (IAP) Product
 Table 50. Gilead Revenue in CD47 (IAP) Business (2020-2025) & (US$ Million)
 Table 51. Gilead Recent Development
 Table 52. Innovent Biologics Company Details
 Table 53. Innovent Biologics Business Overview
 Table 54. Innovent Biologics CD47 (IAP) Product
 Table 55. Innovent Biologics Revenue in CD47 (IAP) Business (2020-2025) & (US$ Million)
 Table 56. Innovent Biologics Recent Development
 Table 57. Akeso, Inc Company Details
 Table 58. Akeso, Inc Business Overview
 Table 59. Akeso, Inc CD47 (IAP) Product
 Table 60. Akeso, Inc Revenue in CD47 (IAP) Business (2020-2025) & (US$ Million)
 Table 61. Akeso, Inc Recent Development
 Table 62. Arch Oncology Company Details
 Table 63. Arch Oncology Business Overview
 Table 64. Arch Oncology CD47 (IAP) Product
 Table 65. Arch Oncology Revenue in CD47 (IAP) Business (2020-2025) & (US$ Million)
 Table 66. Arch Oncology Recent Development
 Table 67. ImmuneOncia Therapeutics Company Details
 Table 68. ImmuneOncia Therapeutics Business Overview
 Table 69. ImmuneOncia Therapeutics CD47 (IAP) Product
 Table 70. ImmuneOncia Therapeutics Revenue in CD47 (IAP) Business (2020-2025) & (US$ Million)
 Table 71. ImmuneOncia Therapeutics Recent Development
 Table 72. I-MAB Company Details
 Table 73. I-MAB Business Overview
 Table 74. I-MAB CD47 (IAP) Product
 Table 75. I-MAB Revenue in CD47 (IAP) Business (2020-2025) & (US$ Million)
 Table 76. I-MAB Recent Development
 Table 77. Sorrento Therapeutics Company Details
 Table 78. Sorrento Therapeutics Business Overview
 Table 79. Sorrento Therapeutics CD47 (IAP) Product
 Table 80. Sorrento Therapeutics Revenue in CD47 (IAP) Business (2020-2025) & (US$ Million)
 Table 81. Sorrento Therapeutics Recent Development
 Table 82. Zai Lab Company Details
 Table 83. Zai Lab Business Overview
 Table 84. Zai Lab CD47 (IAP) Product
 Table 85. Zai Lab Revenue in CD47 (IAP) Business (2020-2025) & (US$ Million)
 Table 86. Zai Lab Recent Development
 Table 87. ImmuneOnco Company Details
 Table 88. ImmuneOnco Business Overview
 Table 89. ImmuneOnco CD47 (IAP) Product
 Table 90. ImmuneOnco Revenue in CD47 (IAP) Business (2020-2025) & (US$ Million)
 Table 91. ImmuneOnco Recent Development
 Table 92. Hengrui Company Details
 Table 93. Hengrui Business Overview
 Table 94. Hengrui CD47 (IAP) Product
 Table 95. Hengrui Revenue in CD47 (IAP) Business (2020-2025) & (US$ Million)
 Table 96. Hengrui Recent Development
 Table 97. Beijing Mab-works Company Details
 Table 98. Beijing Mab-works Business Overview
 Table 99. Beijing Mab-works CD47 (IAP) Product
 Table 100. Beijing Mab-works Revenue in CD47 (IAP) Business (2020-2025) & (US$ Million)
 Table 101. Beijing Mab-works Recent Development
 Table 102. Hanxbio Company Details
 Table 103. Hanxbio Business Overview
 Table 104. Hanxbio CD47 (IAP) Product
 Table 105. Hanxbio Revenue in CD47 (IAP) Business (2020-2025) & (US$ Million)
 Table 106. Hanxbio Recent Development
 Table 107. ALX Oncology Company Details
 Table 108. ALX Oncology Business Overview
 Table 109. ALX Oncology CD47 (IAP) Product
 Table 110. ALX Oncology Revenue in CD47 (IAP) Business (2020-2025) & (US$ Million)
 Table 111. ALX Oncology Recent Development
 Table 112. Surface Oncology Company Details
 Table 113. Surface Oncology Business Overview
 Table 114. Surface Oncology CD47 (IAP) Product
 Table 115. Surface Oncology Revenue in CD47 (IAP) Business (2020-2025) & (US$ Million)
 Table 116. Surface Oncology Recent Development
 Table 117. TG Therapeutics Company Details
 Table 118. TG Therapeutics Business Overview
 Table 119. TG Therapeutics CD47 (IAP) Product
 Table 120. TG Therapeutics Revenue in CD47 (IAP) Business (2020-2025) & (US$ Million)
 Table 121. TG Therapeutics Recent Development
 Table 122. EpicentRx Company Details
 Table 123. EpicentRx Business Overview
 Table 124. EpicentRx CD47 (IAP) Product
 Table 125. EpicentRx Revenue in CD47 (IAP) Business (2020-2025) & (US$ Million)
 Table 126. EpicentRx Recent Development
 Table 127. Research Programs/Design for This Report
 Table 128. Key Data Information from Secondary Sources
 Table 129. Key Data Information from Primary Sources
 Table 130. Authors List of This Report


List of Figures
 Figure 1. CD47 (IAP) Picture
 Figure 2. Global CD47 (IAP) Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global CD47 (IAP) Market Share by Type: 2024 VS 2031
 Figure 4. CD47 Monoclonal Antibody Features
 Figure 5. CD47 Double Antibody Features
 Figure 6. CD47 Fusion Protein Features
 Figure 7. Global CD47 (IAP) Market Size by Application (2020-2031) & (US$ Million)
 Figure 8. Global CD47 (IAP) Market Share by Application: 2024 VS 2031
 Figure 9. Solid Tumor Case Studies
 Figure 10. Lymphoma Case Studies
 Figure 11. Others Case Studies
 Figure 12. CD47 (IAP) Report Years Considered
 Figure 13. Global CD47 (IAP) Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 14. Global CD47 (IAP) Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global CD47 (IAP) Market Share by Region: 2024 VS 2031
 Figure 16. Global CD47 (IAP) Market Share by Players in 2024
 Figure 17. Global Top CD47 (IAP) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD47 (IAP) as of 2024)
 Figure 18. The Top 10 and 5 Players Market Share by CD47 (IAP) Revenue in 2024
 Figure 19. North America CD47 (IAP) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. North America CD47 (IAP) Market Share by Country (2020-2031)
 Figure 21. United States CD47 (IAP) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Canada CD47 (IAP) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe CD47 (IAP) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe CD47 (IAP) Market Share by Country (2020-2031)
 Figure 25. Germany CD47 (IAP) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. France CD47 (IAP) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. U.K. CD47 (IAP) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Italy CD47 (IAP) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Russia CD47 (IAP) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Nordic Countries CD47 (IAP) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific CD47 (IAP) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific CD47 (IAP) Market Share by Region (2020-2031)
 Figure 33. China CD47 (IAP) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Japan CD47 (IAP) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. South Korea CD47 (IAP) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Southeast Asia CD47 (IAP) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. India CD47 (IAP) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Australia CD47 (IAP) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America CD47 (IAP) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America CD47 (IAP) Market Share by Country (2020-2031)
 Figure 41. Mexico CD47 (IAP) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Brazil CD47 (IAP) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa CD47 (IAP) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa CD47 (IAP) Market Share by Country (2020-2031)
 Figure 45. Turkey CD47 (IAP) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Saudi Arabia CD47 (IAP) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. UAE CD47 (IAP) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Gilead Revenue Growth Rate in CD47 (IAP) Business (2020-2025)
 Figure 49. Innovent Biologics Revenue Growth Rate in CD47 (IAP) Business (2020-2025)
 Figure 50. Akeso, Inc Revenue Growth Rate in CD47 (IAP) Business (2020-2025)
 Figure 51. Arch Oncology Revenue Growth Rate in CD47 (IAP) Business (2020-2025)
 Figure 52. ImmuneOncia Therapeutics Revenue Growth Rate in CD47 (IAP) Business (2020-2025)
 Figure 53. I-MAB Revenue Growth Rate in CD47 (IAP) Business (2020-2025)
 Figure 54. Sorrento Therapeutics Revenue Growth Rate in CD47 (IAP) Business (2020-2025)
 Figure 55. Zai Lab Revenue Growth Rate in CD47 (IAP) Business (2020-2025)
 Figure 56. ImmuneOnco Revenue Growth Rate in CD47 (IAP) Business (2020-2025)
 Figure 57. Hengrui Revenue Growth Rate in CD47 (IAP) Business (2020-2025)
 Figure 58. Beijing Mab-works Revenue Growth Rate in CD47 (IAP) Business (2020-2025)
 Figure 59. Hanxbio Revenue Growth Rate in CD47 (IAP) Business (2020-2025)
 Figure 60. ALX Oncology Revenue Growth Rate in CD47 (IAP) Business (2020-2025)
 Figure 61. Surface Oncology Revenue Growth Rate in CD47 (IAP) Business (2020-2025)
 Figure 62. TG Therapeutics Revenue Growth Rate in CD47 (IAP) Business (2020-2025)
 Figure 63. EpicentRx Revenue Growth Rate in CD47 (IAP) Business (2020-2025)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

HSP47 ELISA Kit Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global CD3E Market Research Report 2025
Global GFAP Antibody Market Research Report 2024
Global Immune Checkpoint Agents Market Research Report 2025
Global IABP Balloon Catheters Market Research Report 2025
Global Flow Cytometry Antibody Products Market Research Report 2025
Global Iopromide Market Research Report 2025
Global Cell Therapy CDMO Market Research Report 2025
Global Macrophage Stimulating Protein Receptor Market Research Report 2025
Global Human Immunoassay Market Research Report 2025
Global HIV 1 Screening Tests Market Research Report 2025
Global Tripeptide 29 Market Research Report 2025
Global Membrane Potential Assay Kits Market Research Report 2025
Global Leukocyte Surface Antigen CD47 Market Research Report 2024
Global Anti CD19 Market Research Report 2024
Global 77PD 3081 14 9 Market Research Report 2025
Global Daratumumab Market Research Report 2024
Global dPCR Platforms Market Research Report 2025
Global Trastuzumab Market Research Report 2025
Global Health Product for Immune Market Research Report 2024

RELATED REPORTS

Global GLP-1 Targeted Peptide Weight Loss Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19A18322
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Stimulant-Free Fat Burners Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3E3525
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Test Boosters Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35T3049
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Salsalate Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-33Y1801
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions